Skip to main content
SpringerLink
Log in

Comparison of omeprazole and ranitidine in treatment of refractory gastroesophageal reflux disease in patients with gastric acid hypersecretion

  • Original Articles
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Secretion of gastric acid and volume, serum gastrin concentration, and ambulatory 24-hr esophageal pH monitoring were evaluated prospectively in 12 patients with idiopathic gastric acid hypersecretion (basal acid output greater than 10.0 meq/hr) undergoing treatment for refractory chronic long-standing pyrosis. Treatment lasted six months and consisted of three months of ranitidine (mean 2150 mg/day, range 1200–3000 mg/day), followed by three months of omeprazole (mean 33 mg/day, range 20–60 mg/day). Both ranitidine and omeprazole significantly reduced gastric acid output (P<0.001) and gastric volume output (P<0.001) compared to a basal evaluation and resulted in complete disappearance of pyrosis. Total reflux time (percent 24 hr intraesophageal pH less than 4) was significantly reduced by ranitidine (P<0.02) and omeprazole (P<0.001) compared to basal evaluation; however, the effects of omeprazole were significantly greater than ranitidine (P<0.05). Omeprazole caused a significant increase in serum gastrin concentration compared to both basal and ranitidine (P<0.05). Endoscopically documented erosive esophagitis was present in nine of the 12 patients, and seven of the 12 patients had Barrett's epithelium. All 12 patients had complete resolution of pyrosis and healed esophagitis by six months, but no significant endoscopic regression was observed in the extent of Barrett's epithelium. No side effects occurred with these high doses of ranitidine or omeprazole. These results indicate that high-dose ranitidine and omeprazole are effective therapy for refractory gastroesophageal reflux disease. However, with omeprazole, total reflux times are reduced more than with ranitidine, often into the normal range. That marked reduction of gastric acid secretion with omeprazole, which greatly reduces total reflux times, accounts for the significant elevation of serum gastrin concentration seen during omeprazole therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Richter JE, Castell DO: Gastroesophageal reflux: pathogenesis, diagnosis, and therapy. Ann Intern Med 97:93–103, 1982

    Google Scholar 

  2. Miller LS, Vinayek R, Frucht H, Gardner JD, Jensen RT, Maton PN: Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology 98:341–346, 1990

    Google Scholar 

  3. Evander A, Little AG, Riddell RH, Walther B, Skinner DB: Composition of the refluxed material determines the degree of reflux esophagitis in the dog. Gastroenterology 93:280–286, 1987

    Google Scholar 

  4. Goldberg HI, Dodds WJ, Gee S, Montgomery C, Zboralske FF: Role of acid and pepsin in acute experimental esophagitis. Gastroenterology 56:223–230, 1969

    Google Scholar 

  5. Lillemoe KD, Johnson LF, Harmon JW: Role of the components of the gastroduodenal contents in experimental acid esophagitis. Surgery 92:276–284, 1982

    Google Scholar 

  6. Collen MJ, Gallagher JE: Basal acid output and gastric acid hypersecretion in patients with gastroesophageal reflux disease. Gastroenterology 98:32, 1990 (abstract)

    Google Scholar 

  7. Collen MJ, Johnson DA: Correlation between basal acid output and daily ranitidine dose required for therapy in Barrett's esophagus. Dig Dis Sci 1991 (in press)

  8. Collen MJ, Lewis JH, Benjamin SB: Gastric acid hypersecretion in refractory gastroesophageal reflux disease. Gastroenterology 98:654–661, 1990

    Google Scholar 

  9. Lee FI, Isaacs PET: Barrett's ulcer: Response to standard dose ranitidine, high dose ranitidine and omeprazole. Am J Gastroenterol 83:914–916, 1988

    Google Scholar 

  10. Dammann HG, Blum AL, Lux G: Omeprazole is superior to ranitidine in the treatment of reflux esophagitis. Gastroenterology 90:1385, 1986 (abstract)

    Google Scholar 

  11. Klinkenberg-Knol EC, Jansen JMBJ, Festen HPM, Meuwissen SGM, Lamers CBHW: Double-blind multicenter comparison of omeprazole and ranitidine in the treatment of reflux esophagitis. Lancet 1:349–351, 1987

    Google Scholar 

  12. Vantrappen G, Rutgeerts L, Schurmans P, Coenegrachts J-L: Omeprazole (40 mg) is superior to ranitidine in the short-term treatment of ulcerative reflux esophagitis. Dig Dis Sci 33:523–529, 1988

    Google Scholar 

  13. Zeitoun P, Desjars De Keranroue N, Isal JP: Omeprazole versus ranitidine in erosive esophagitis. Lancet 2:621–622, 1987 (letter)

    Google Scholar 

  14. Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, McCarthy JH, Mitchell B, Beveridge BR, Laurence BH, Gibson GG, Grant AK, Shearman DJC, Whitehead R, Buckle PJ: Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95:903–912, 1988

    Google Scholar 

  15. Knuff TE, Benjamin SB, Worsham F, Hancock JE, Castell DO: Histologic evaluation of chronic gastroesophageal reflux. An evaluation of biopsy methods and diagnostic criteria. Dig Dis Sci 29:194–201, 1984

    Google Scholar 

  16. Winters C, Spurling TJ, Chobanian SJ, Curtis DJ, Esposito RL, Hacker JF, Johnson DA, Cruess DF, Cotelingham JD, Guerney MS, Cattau EL: Barrett's esophagus: a prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 91:118–124, 1987

    Google Scholar 

  17. Emde C, Garner A, Blum AL: Technical aspects of intraluminal pH-metry in man: Current status and recommendations. Gut 28:1177–1188, 1987

    Google Scholar 

  18. Diet Manual, 5th ed. Washington, D.C., Georgetown University Hospital, 1980, pp 221–222

  19. Raufman J-P, Collins SM, Pandol SJ, Collen MJ, Cornelius MJ, Feld MK, McCarthy DM, Gardner JD, Jensen RT: Reliability of symptoms in assessing control of gastric acid secretion in patients with Zollinger-Ellison syndrome. Gastroenterology 84:108–113, 1983

    Google Scholar 

  20. Collen MJ, Sheridan MJ: Definition for idiopathic basal gastric acid hypersecretion: A statistical and functional evaluation. Dig Dis Sci 1991 (in press)

  21. Wolfe MM, Jensen RT: Zollinger-Ellison syndrome. Current concepts in diagnosis and management. N Engl J Med 317:1200–1209, 1987

    Google Scholar 

  22. Cochran WG, Snedecor GW: Statistical Methods, 7th ed. Ames, Iowa, Iowa State University Press, 1980

    Google Scholar 

  23. Collen MJ, LaMont B, Benjamin SB, Berlin RG: Inhibition of gastric acid secretion: No correlation between ranitidine and omeprazole. Gastroenterology 96:94, 1989 (abstract)

    Google Scholar 

  24. Wesdrop E, Bartelsman J, Pape K, Dekker W, Tytgat GN: Oral cimetidine in reflux esophagitis: A double blind controlled trial. Gastroenterology 74:821–824, 1978

    Google Scholar 

  25. Behar J, Brand DL, Brown FC, Castell DO, Cohen S, Crossley RJ, Pope CE, Winans CS: Cimetidine in the treatment of symptomatic gastroesophagel reflux. A double blind controlled trial. Gastroenterology 74:821–824, 1978

    Google Scholar 

  26. Fiasse R, Hanin C, Lepot A, Descamps D, Lamy F, Dive C: Controlled trial of cimetidine in reflux esophagitis. Dig Dis Sci 93:926–927, 1980

    Google Scholar 

  27. Castell DO: Medical therapy of reflux esophagitis. Ann Intern Med 93:926–927, 1980

    Google Scholar 

  28. Kaul B, Petersen H, Erichsen H, Myrvold HE, Grette K, Halvorsen T, Fjosne U: Gastroesophageal reflux disease: Acute and maintenance treatments with cimetidine. Scand J Gastroenterol 21:139–145, 1986

    Google Scholar 

  29. Wesdorp ICE, Dekker W, Klinkenberg-Knol EC: Treatment of reflux esophagitis with ranitidine. Gut 24:921–924, 1983

    Google Scholar 

  30. Sherbanik R, Wengel R, Bailey R, Trautman A, Grace M, Kirkeikis P, Jewell L, Pare P, Levesgue D, Farley A: Ranitidine in the treatment of symptomatic gastroesophageal reflux disease. J Clin Gastroenterol 6:9–15, 1984

    Google Scholar 

  31. Koelz HR, Birchler R, Bretholz A, Bron B, Capitaine Y, Delmore G, Fehr HF, Fumagalli I, Gehrig J, Gonvers JJ, Halter F, Hammer B, Kayasseh L, Kobler E, Miller G, Munst G, Pelloni S, Realini S, Schmid P, Voirol M, Blum AL: Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology 91:1198–1205, 1986

    Google Scholar 

  32. Johansson K-E, Boeryd B, Johansson K, Tibbling L: Double-blind crossover study of ranitidine and placebo in gastroesophageal reflux disease. Scand J Gastroenterol 21:769–778, 1986

    Google Scholar 

  33. Sontag S, Robinson M, McCallum RW, Barwick KW, Nardi R: Ranitidine therapy for gastroesophageal reflux disease: Results of a large double-blind trial. Arch Intern Med 147:1485–1491, 1987

    Google Scholar 

  34. Sekigucki T, Nishioka T, Kogure M, Kusano M, Horikoshi T, Sugiyama T, Kobayashi S: Once-daily administration of famotidine for reflux esophagitis. Scand J Gastroenterol 22(suppl 134):51–54, 1987

    Google Scholar 

  35. Dodds WJ, Dent J, Hogan WJ, Helm JF, Hauser R, Patel GK, Egide MS: Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med 307:1547–1552, 1982

    Google Scholar 

  36. Dent J, Dodds WJ, Hogan WJ, Toouli J: Factors that influence induction of gastroesophageal reflux in normal human subjects. Dig Dis Sci 37:270–275, 1988

    Google Scholar 

  37. Collen MJ: Idiopathic gastric acid hypersecretory states. Gastroenterology 96:93, 1989 (abstract)

    Google Scholar 

  38. Collen MJ, Stanczak VJ, Ciarleglio CA: Refractory duodenal ulcers (nonhealing duodenal ulcers with standard doses of antisecretory medication). Dig Dis Sci 34:233–237, 1989

    Google Scholar 

  39. Maton PN, Vinayek R, Frucht H, McArthur KA, Miller LS, Saeed ZA, Gardner JD, Jensen RT: Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: A prospective study. Gastroenterology 97:827–836, 1989

    Google Scholar 

  40. Castell DO: Medical assessment of the patient with Barrett's esophagus.In Barrett's Esophagus. SJ Spechler, RK Goyal (eds). New York, Elsevier, 1985, pp 199–209

    Google Scholar 

  41. Clissold SP, Campoli-Richards DM: Omeprazole: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs 32:15–47, 1986

    Google Scholar 

  42. Fiorucci S, Santucci L, Abbritti F, Farroni F, Morelli A: Effect of omeprazole on 24-hr endogastric and esophageal pH in patients with severe esophagitis and Barrett's esophagus. Gastroenterology 94:129, 1988 (abstract)

    Google Scholar 

  43. Baldi F, Ferrarini F, Balestra R, Borioni D, Brunetti G, Barbara L: Oesophageal function after oral ranitidine: An acute double blind study in normal subjects. Hepatogastroenterology 31:38–40, 1984

    Google Scholar 

  44. Johnson LF, Harmon JW: Experimental esophagitis in a rabbit model. J Clin Gastroenterol 21(suppl 1):26–44, 1986

    Google Scholar 

  45. Wallmark B: Mechanism of action of omeprazole. Scand J Gastroenterol 21(suppl):11–16, 1986

    Google Scholar 

  46. Brater DC, Peters MN, Eshelman FN, Richardson CT: Clinical comparison of cimetidine and ranitidine. Clin Pharmacol Ther 32:484–489, 1982

    Google Scholar 

  47. Hirschowitz BI, Danilewitz M, Molina E: Inhibition of basal acid, chloride, and pepsin secretion in duodenal ulcer by graded doses of ranitidine and atropine with studies of pharmacokinetics of ranitidine. Gastroenterology 82:1314–1326, 1982

    Google Scholar 

  48. Collen MJ, Howard JM, McArthur KE, Raufman J-P, Cornelius MJ, Ciarleglio CA, Gardner JD, Jensen RT: Comparison of ranitidine and cimetidine in the treatment of gastric acid hypersecretion. Ann Intern Med 100:52–58, 1984

    Google Scholar 

  49. Howard JM, Chremos AN, Collen MJ, McArthur KE, Cherner JA, Maton PN, Ciarleglio CA, Cornelius MJ, Gardner JD, Jensen RT: Famotidine, a new, potent, long-acting histamine H2-receptor antagonists: Comparison with cimetidine and ranitidine in the treatment of Zollinger-Ellison syndrome. Gastroenterology 88:1026–1033, 1985

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Department of Medicine, Loma Linda University Medical Center, Loma Linda, California

    Martin J. Collen MD & Richard M. Strong MD

Authors
  1. Martin J. Collen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard M. Strong MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Collen, M.J., Strong, R.M. Comparison of omeprazole and ranitidine in treatment of refractory gastroesophageal reflux disease in patients with gastric acid hypersecretion. Digest Dis Sci 37, 897–903 (1992). https://doi.org/10.1007/BF01300388

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01300388

Key Words

Search

Navigation